Prosecution Insights
Last updated: April 19, 2026

Examiner: TRUONG, QUANGLONG N

Tech Center 1600 • Art Units: 1615

This examiner grants 79% of resolved cases

Performance Statistics

79.1%
Allow Rate
+19.1% vs TC avg
675
Total Applications
+23.2%
Interview Lift
884
Avg Prosecution Days
Based on 626 resolved cases, 2023–2026

Rejection Statute Breakdown

4.0%
§101 Eligibility
11.1%
§102 Novelty
52.4%
§103 Obviousness
19.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17616439 ULTRAVIOLET ABSORBER, PREPARATION METHOD THEREFOR, AND ULTRAVIOLET SCREENING PRODUCT CONTAINING SAME Non-Final OA UNIST(ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)
18711268 BIOFILM-TARGETING NANOPARTICLES TO INCREASE THE ANTICARIES EFFECT OF FLUORIDE Non-Final OA The Regents of The University of Michigan
18573917 COMPOSITION COMPRISING N,N-DICARBOXYMETHYLGLUTAMIC ACID, 1,3-PROPANEDIOL, AT LEAST ONE NONIONIC SURFACTANT, AT LEAST ONE ALKALINE AGENT AND/OR AT LEAST ONE DYE Non-Final OA L'Oreal
18683397 CANCER THERAPEUTIC AGENT Non-Final OA UNITED IMMUNITY, CO., LTD.
18245425 ORAL DRUG DELIVERY DEVICE WITH EXPANDING BAND Non-Final OA Eli Lilly and Company
18566778 A PHOTORESPONSIVE DELIVERY SYSTEM BASED ON A MODIFIED PAMAM AND METHODS THEREOF Non-Final OA THE UNIVERSITY OF HONG KONG
18475416 GUMMY DOSAGE FORMS Final Rejection Kenvue Brands LLC
18664718 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF Non-Final OA Avalyn Pharma Inc.
18697398 MNO NANOMATERIAL BASED INHIBITORS OF INFLAMMATION AND SARS-COV-2 VIRAL REPLICATION Non-Final OA NewSouth Innovations Pty Limited
18697878 COMPOSITIONS AND METHODS FOR LEVODOPA DELIVERY Non-Final OA NANOMERICS LTD.
18697489 DRESSING FOR TREATING HARD-TO-HEAL WOUNDS AND A PROCESS FOR THE MANUFACTURE THEREOF Non-Final OA Warszawski Uniwersytet Medyczny
18697615 SUSTAINED RELEASE INJECTABLE PHARMACEUTICAL FORMULATION OF LEVOTHYROXINE AND PROCESS FOR PREPARATION THEREOF Non-Final OA PHARMATHEN S.A.
18697370 ORAL LIQUID ENZALUTAMIDE COMPOSITIONS Non-Final OA FERRING B.V.
18696785 COMPOSITIONS OF DECIDUA TISSUE AND USES THEREOF Non-Final OA OSIRIS THERAPEUTICS, INC.
18696000 COMPOSITIONS FOR ENHANCING PESTICIDES Non-Final OA TERRAMERA, INC.
17310241 SUNSCREEN COMPOSITIONS Non-Final OA BEIERSDORF AG
18587982 RETINOL DERIVATIVE COMPOSITION AND USE THEREOF Non-Final OA DermaHealth Shanghai Biotechnology Co., Ltd.
18682685 LIPID NANOPARTICLE FORMULATIONS AND METHODS OF SYNTHESIS THEREOF Non-Final OA ModernaTX, Inc.
18432125 Implantable Device for Release of Glucagon-Like Peptide-1 Receptor Agonist Non-Final OA Celanese EVA Performance Polymers LLC
18576196 PHARMACEUTICAL COMPOSITION FOR RESTORING PHYSIOLOGICAL PROCESSES AND CELLS OF ORGANISM Non-Final OA Abdula KURKAYEV
18571529 HAIR GROWTH AGENT Non-Final OA ADJUVANT HOLDINGS CO., LTD.
18285918 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS Non-Final OA Avantor Performance Materials, LLC
17864120 FLUID EXCHANGE APPARATUS FOR EXPANDABLE PORT DELIVERY SYSTEM AND METHODS OF USE Non-Final OA ForSight Vision4, Inc.
18553344 EDIBLE PRODUCTS AND COMPOSITIONS FOR EDIBLE PRODUCTS Non-Final OA Jelly Drops Limited
18256754 METHISOPRINOL COMPOSITIONS Non-Final OA REENA PATEL
18179863 TINCTURE CONTAINING CANNABINOIDS, METHOD OF USING, AND METHOD OF MAKING THE SAME Non-Final OA Holistic Hemp Solutions, Inc.
18255796 TRANSMUCOSAL DELIVERY OF TOCOTRIENOLS Non-Final OA INVICTUS BIOTECHNOLOGY PTY LTD
18014168 COMPOSITION USED AS A MOOD-REGULATING STIMULANT Non-Final OA HAPPYGUM G.M.B.H.
17792196 AN ADHESIVE BODY DRESSING AND METHOD FOR MANUFACTURING AN ADHESIVE BODY DRESSING Non-Final OA DERMECO OY
17434200 THERMALLY STABLE ANTIBACTERIAL QUATERNARY AMMONIUM NANOPARTICLES Non-Final OA NOBIO LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month